Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people

  • Technology appraisal guidance
  • TA300
  • Published: 

History

Review proposal consultation

Background information

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: final appraisal determination

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: appraisal consultation

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: equality impact assessment - guidance review

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: Assessment report

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: appendix B - final scope

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: appendix C - final matrix

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: appendix D - response to comments on the draft scope

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: Equality impact assessment form (scoping)

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: final protocol

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: draft scope

Hepatitis C (children and young people) - peginterferon alfa and ribavirin: provisional matrix